Literature DB >> 14561573

Potential association of thyrotoxicosis with vitamin B and folate deficiencies, resulting in risk for hyperhomocysteinemia and subsequent thromboembolic events.

Kathleen M Colleran1, Devona M Ratliff, Mark R Burge.   

Abstract

OBJECTIVE: To describe a patient with severe thyrotoxicosis attributable to Graves' disease who had a thrombotic cerebrovascular accident and hyperhomocysteinuria, which resolved on correction of the thyrotoxicosis, and to present findings in a pilot study undertaken to investigate the relationship among thyrotoxicosis, homocysteine, folate, and vitamin B(12).
METHODS: We present a case report of the index case, with clinical and laboratory details. For the investigative analysis, 21 patients who were 18 to 50 years old and had newly diagnosed, untreated Graves' disease and 10 age-and sex-matched euthyroid control subjects were studied. Of the patients with Graves' disease, 11 underwent studies both at diagnosis and after treatment. Fasting blood tests were performed for thyrotropin, free thyroxine, homocys-teine, vitamin B(12), folate, and methylmalonic acid, a marker of vitamin B(12) deficiency.
RESULTS: Vitamin B(12), folate, homocysteine, and methylmalonic acid levels were not significantly different between the thyrotoxic and control or posttreatment groups. In patients with thyrotoxicosis, however, free thyroxine was positively correlated with both homocysteine (r = 0.67; P = 0.03) and methylmalonic acid (r = 0.89; P = 0.003).
CONCLUSION: The positive correlation between free thyroxine levels and both homocysteine and methylmalonic acid suggests that thyrotoxicosis may be associated with functional vitamin B(12) deficiency. Such a deficiency may result in clinically important hyperhomocysteine-mia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561573     DOI: 10.4158/EP.9.4.290

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  6 in total

Review 1.  Concurrent Graves' disease and intracranial arterial stenosis/occlusion: special considerations regarding the state of thyroid function, etiology, and treatment.

Authors:  Shigeo Ohba; Toru Nakagawa; Hideki Murakami
Journal:  Neurosurg Rev       Date:  2011-03-19       Impact factor: 3.042

2.  Lipid abnormalities and cardiometabolic risk in patients with overt and subclinical thyroid disease.

Authors:  Melpomeni Peppa; Grigoria Betsi; George Dimitriadis
Journal:  J Lipids       Date:  2011-07-18

3.  Fatal outcome in a Hispanic woman with moyamoya syndrome and Graves' disease.

Authors:  Julian Choi; Perin Suthakar; Farbod Farmand
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-11-04

4.  Association of Hyperthyroidism and Thyroid Autoantibodies with Moyamoya Disease and Its Stroke Event: A Population-based Case-control Study and Meta-analysis.

Authors:  Jun Hyong Ahn; Jin Pyeong Jeon; Jeong Eun Kim; Eun Jin Ha; Won-Sang Cho; Young Joo Park; Nam Han Cho; Hoon Sung Choi; Hyun-Seung Kang; Young-Je Son; Jae Seung Bang; Chang Wan Oh
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-01-19       Impact factor: 1.742

Review 5.  A case of Moyamoya disease in a girl with thyrotoxicosis.

Authors:  Ran Lee; Kihye Sung; Yong Mean Park; Jeong Jin Yu; Young-Cho Koh; Sochung Chung
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759

6.  Two adolescent patients with coexistent Graves' disease and Moyamoya disease in Korea.

Authors:  Chong Kun Cheon; Su Yung Kim; Jae-Ho Yoo
Journal:  Korean J Pediatr       Date:  2014-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.